GPI-phosphoethanolamine Transferase Inhibitor Development Service

GPI-phosphoethanolamine Transferase Inhibitor Development Service

GPI-phosphoethanolamine Transferase (GPI-PET) Inhibitor Development Service at CD BioGlyco

GPI-PET is an enzyme involved in the modification of GPI-anchored proteins by phosphoethanolamine. During the synthesis of mammalian GPI anchors, three different GPI-PETs add phosphoethanolamine (P-EthN) groups to each of the three Man residues in the GPI glycan core. This step is critical for GPI anchoring because the P-EthN group provides the link between the glycolipid and the protein. CD BioGlyco has one-stop Glycosylation Inhibitor Development solutions, and we provide you with an efficient and flexible GPI-PET inhibitor development service.

  • Flexible inhibitor screening service

CD BioGlyco provides high-quality GPI-PET inhibitor development services in multiple pathways.

    • We use methods such as high-throughput screening (HTS) to screen compound libraries to find potential GPI-PET inhibitors. The screened inhibitors are chemically modified and structurally optimized to improve their inhibitory activity and physical and chemical properties.
    • We design and develop specific antibodies or protein inhibitors that interfere with the functions of GPI-PET.
    • We use RNA interference technology to interfere with the expression of the GPI-PET gene, thereby inhibiting its functions.
    • In addition, we also use clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9) gene editing technology to perform targeted editing or silencing of the GPI-PET gene to achieve GPI-PET inhibition.
  • Activity assessment service

CD BioGlyco provides efficient GPI-PET inhibitor evaluation services to verify their inhibitory efficacy and selectivity.

    • Inhibitor preparation: We prepare and purify the GPI-PET inhibitors to be evaluated through chemical synthesis, isolation, and purification.
    • Enzyme activity assay: We use appropriate enzyme activity assay methods, such as fluorescent enzyme activity assays, radioactive assays, etc., to evaluate the activity of GPI-PET enzymes.
    • Concentration-dependent study: We provide study services on the effect of inhibitors on GPI-PET activity at different concentrations. By drawing the inhibitory activity curve and calculating the half-maximal inhibitory concentration (IC50), we determine the potential inhibitory ability of the inhibitor on GPI-PET.
    • Cell-level evaluation: At the same time, we provide an assessment of the biosynthesis of GPI-anchored proteins by inhibitors, such as detecting the expression, secretion, or cellular localization of GPI-anchored proteins.
  • Inhibitor production service

In addition, CD BioGlyco provides mature GPI-PET inhibitor production service. We select appropriate synthesis routes, reaction conditions, catalysts, solvents, and other process conditions to optimize the production process of GPI-PMT inhibitors, thereby ensuring that the production process is efficient, repeatable, and has good product yields.

Fig.1 GPI-PET inhibitor development service. (CD BioGlyco)Fig.1 GPI-PET inhibitor development service. (CD BioGlyco)


Technology: Thin-layer chromatography

Journal: Biochemistry

IF: 3.321

Published: 2001

Results: The authors studied the mechanism of action of 1,10-phenanthroline (PNT) on GPI anchor synthesis. PNT was added to HeLa cells. As its concentration increased, the level of H6 reached a maximum at 100 μM PNT, while H2 detected that higher PNT concentrations resulted in greater H2 accumulation and a parallel decrease in H6. Studies showed that PNT was a novel inhibitor of GPI-anchored synthesis that caused the accumulation of GPI-anchored intermediates that were substrates for GPI-PET, suggesting that these enzymes were targets of PNT.

Fig.2 Dose-dependent inhibition of GPI synthesis by PNT. (Mann & Sevlever, 2001)Fig.2 Dose-dependent inhibition of GPI synthesis by PNT. (Mann & Sevlever, 2001)


  • Disease research: GPI-anchored proteins are related to a variety of diseases, such as congenital diseases and neurological diseases. The development of GPI-PET inhibitors helps further understand the mechanism of GPI modification in these diseases and may provide new potential targets for the research of related diseases.
  • Drug screening and development: Developing inhibitors against GPI-PET are used for drug screening and development. Potential drug candidates are discovered by screening a library of compounds with GPI-PET inhibitory activity.
  • Bioengineering and production: GPI-anchored proteins have important applications in bioengineering and production. The development of GPI-PET inhibitors provides a means to control GPI modifications in industrial production and regulate product expression, purification, and functions.


  • Advanced experimental facilities: CD BioGlyco is equipped with advanced laboratory facilities and instruments to support efficient GPI-PET inhibitor screening, optimization, and evaluation.
  • Diverse screening means: We have diverse screening means, including cell lines, enzyme reactions, or in vivo models, to quickly evaluate the activity and selectivity of candidate GPI-PET inhibitors.
  • Custom services: We provide custom GPI-PET inhibitor development services efficiently and flexibly, and we will provide the best solutions for different stages of inhibitor development.

CD BioGlyco continues to pay attention to the latest industry research progress and technological innovation. We apply the latest scientific methods to the development of GPI-PET inhibitors and provide you with optimal GPI-PET inhibitor development services. Please feel free to contact us if you would like to get specific development details.


  1. Mann, K.J.; Sevlever, D. 1, 10-Phenanthroline inhibits glycosylphosphatidylinositol anchoring by preventing phosphoethanolamine addition to glycosylphosphatidylinositol anchor precursors. Biochemistry. 2001, 40(5): 1205-1213.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.